胡俊　杨盼盼　陶阳　沈云峰

【摘要】 目的：探讨芪骨胶囊联合塞来昔布治疗膝骨关节炎的效果及对膝关节功能和炎性因子水平的影响。方法：选取2018年1月-2019年12月本院治疗的110例膝骨关节炎患者，根据随机数字表法分为观察组和研究组，每组55例。对照组采用塞来昔布治疗，观察组在对照组的基础上加用芪骨胶囊。比较两组临床疗效、不良反应发生情况及治疗前后的膝关节功能和炎性因子（MMP-1、TNF-α、MMP-3）水平。結果：治疗前，两组WOMAC评分比较，差异无统计学意义（P>0.05）;治疗后，两组WOMAC评分均低于治疗前，且观察组WOMAC评分为（20.26±2.85）分，低于对照组的（26.17±3.05）分，差异均有统计学意义（P<0.05）。观察组总有效率为96.36%高于对照组的85.45%，差异有统计学意义（P<0.05）。治疗前，两组MMP-1、TNF-α、MMP-3比较，差异均无统计学意义（P>0.05）;治疗后，观察组MMP-1、TNF-α、MMP-3分别为（0.39±0.06）、（1.12±0.23）、（10.18±1.25）μg/L，均低于对照组的（0.52±0.11）、（1.45±0.29）、（12.42±1.36）μg/L，差异均有统计学意义（P<0.05）。两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论：芪骨胶囊联合塞来昔布可提高膝骨关节炎患者临床疗效，降低炎性因子水平，加快膝关节功能恢复，安全可靠。

【关键词】 膝骨关节炎 芪骨胶囊 塞来昔布 膝关节功能 炎性因子 不良反应

Clinical Efficacy of Qigu Capsules Combined with Celecoxib in the Treatment of Knee Osteoarthritis and Its Effect on Knee Joint Function/HU Jun， YANG Panpan， TAO Yang， SHEN Yunfeng. //Medical Innovation of China， 2021， 18（23）： 0-089

[Abstract] Objective： To investigate the effect of Qigu Capsules combined with Celecoxib in the treatment of patients with knee osteoarthritis and its influence on knee joint function and inflammatory factor levels. Method： A total of 110 patients with knee osteoarthritis treated in our hospital from January 2018 to December 2019 were selected， and they were divided into observation group and control group according to the random number table method， 55 cases in each group. The control group was treated with Celecoxib， and the observation group was treated with Qigu Capsules on the basis of the control group. The clinical efficacy， adverse reactions were compared between two groups， the knee joint function， inflammatory factor （MMP-1， TNF-α， MMP-3） levels before and after treatment were compared between the two groups. Result： Before treatment， there was no significant difference in WOMAC scores between two groups （P>0.05）; after treatment， the WOMAC scores of the two groups were lower than those before treatment， and the WOMAC score of the observation group was （20.26±2.85） points， which was lower than （26.17±3.05） points of the control group， the differences were statistically significant （P<0.05）. The total effective rate of the observation group was 96.36%， higher than 85.45% of the control group， the difference was statistically significant （P<0.05）. Before treatment， there were no significant differences in MMP-1， TNF-α and MMP-3 between two groups （P>0.05）; after treatment， MMP-1， TNF-α， MMP-3 of the observation group were （0.39±0.06）， （1.12±0.23）， （10.18±1.25） μg/L， lower than （0.52±0.11）， （1.45±0.29）， （12.42±1.36） μg/L of the control group， the differences were statistically significant （P<0.05）. There was no significant difference in the incidence of adverse reactions between two groups （P>0.05）. Conclusion： Qigu Capsules combined with Celecoxib can improve the clinical efficacy of patients with knee osteoarthritis， reduce the level of inflammatory factors， and accelerate the recovery of knee joint function， which is safe and reliable.

[Key words] Knee osteoarthritis Qigu Capsules Celecoxib Knee joint function Inflammatory factor Adverse reactions

First-author’s address： Hongdu Hospital of Traditional Chinese Medicine Affiliated to Jiangxi University of Traditional Chinese Medicine， Nanchang 330000， China

doi：10.3969/j.issn.1674-4985.2021.23.021

膝骨关节炎以膝关节软骨退变和骨质增生为特征，随着膝关节炎症逐渐发展，可引起膝关节疼痛、肿胀、僵硬等症状，使患者活动功能受限，日常活动能力下降[1]。目前，临床治疗该病多以药物为主，塞来昔布属于非甾体消炎药，可有效抑制膝骨关节炎症反应，加快肿胀消退，减轻患者疼痛[2-3]。但单一药物治疗难以取得理想效果，病情易反复。……